BTIG Reiterates Buy Rating for Kymera Therapeutics
BTIG continues to see potential in Kymera Therapeutics with a $134 price target, a 23.94% upside from the current price.
Key Points
- BTIG reiterated its buy rating for Kymera Therapeutics, Inc. (KYMR) with a price target of $134 on June 25, 2026.
- BTIG's $134 price target implies 23.94% upside from Kymera Therapeutics, Inc.'s ($KYMR) current $108.12 share price.
- On Thursday, shares of Kymera Therapeutics traded near $99.87, with a market cap of approximately $8.18 billion.
- Kymera Therapeutics saw insider sales by key executives and continued strong institutional interest, with significant holdings by T. Rowe Price and others.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
BTIG reiterated its buy rating for Kymera Therapeutics, Inc. (NasdaqGM: KYMR) on June 25, 2026, maintaining a price target of $134. This reflects continued confidence in the biotechnology company's prospects.
BTIG vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Kymera Therapeutics, Inc. Stock Down 8.5%
Shares of NasdaqGM:KYMR traded near $99.87 on Thursday. Kymera Therapeutics has a market cap of approximately $8.18 billion. The company currently has no meaningful P/E ratio as it is not profitable, with a beta of 2.027, indicating higher volatility compared to the market. The stock has seen a 52-week low of $36.65 and a high of $105.00. It has a 50-day moving average of $83.06 and a 200-day moving average of $73.55.
$KYMR price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Kymera Therapeutics, Inc.
Recent insider activity at Kymera Therapeutics included several sales and one purchase on June 22, 2026. Chief Business Officer Noah Goodman sold 2,500 shares at $99.00, while Bruce Booth executed planned sales totaling over 278,000 shares at various prices. Goodman also bought 2,500 shares at $21.05, showcasing mixed insider sentiment.
Analysts Set New Price Targets
On June 25, 2026, BTIG reiterated its buy rating for Kymera Therapeutics with a $134 price target. Previously, Canaccord Genuity initiated coverage with a buy rating and a $106 target on May 6, 2026. Jefferies assumed a buy rating with a $110 target on March 16, 2026. The consensus among analysts is a strong buy, with a mean target price of $119.19 based on 21 opinions.
About Kymera Therapeutics
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. It focuses on developing small molecule drugs that target and degrade disease-causing proteins. The company is working on several treatments, including KT-621 for atopic dermatitis and other conditions, KT-579 for autoimmune diseases, and KT-485/SAR447971 for inflammatory diseases. Kymera also collaborates with Sanofi to develop certain drug candidates.
Bottom Line
BTIG's reiterated buy rating and $134 target for Kymera Therapeutics highlight ongoing confidence in the company's potential. Investors should note that this analysis is backward-looking, based on available data and current market conditions. As always, it's essential to conduct thorough research before making any investment decisions.
Get Kymera Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $KYMR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.